Thermo Fisher Scientific Launches Integrated Drug Development Suite

Pharmaceutical and biotechnology companies are facing increasing challenges in drug development due to rising costs, complex regulations, and heightened scientific demands. In response, **Thermo Fisher Scientific** has unveiled its **Accelerator Drug Development** suite, which integrates Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) capabilities. This new offering aims to streamline the entire drug development process, from initial research to commercialisation.

In a recently released sponsored video, **Alberto Fernández**, Head of Clinical Development Strategy & Innovation at Thermo Fisher Scientific, provided insights into how this integrated approach can cater to the needs of both small and mid-sized biotech firms, as well as larger pharmaceutical companies. “By combining various services into one cohesive offering, we can enhance efficiency and reduce the time it takes to bring new therapies to market,” he explained.

The **Accelerator Drug Development** solution is designed to tackle the complexities of modern drug development. By consolidating multiple services under one umbrella, Thermo Fisher aims to alleviate the burdens that come with coordinating between different vendors. This approach is particularly beneficial given the escalating costs associated with drug development, which can exceed **$2.6 billion** per drug, according to a study by the **Tufts Center for the Study of Drug Development**.

Expertise Driving Innovation

Alberto Fernández brings over 32 years of experience in the life sciences and pharmaceutical research and development sector. His career commenced as a Clinical Research Associate in Spain, progressing through roles of increasing responsibility, ultimately leading executive operations at both **GSK** and **AstraZeneca**. At Thermo Fisher, he focuses on implementing forward-thinking strategies that leverage digital tools and artificial intelligence to modernise operations in clinical research.

In his current role, Fernández collaborates across various corporate functions to ensure that innovative solutions are not only developed but also effectively integrated into the workflows of clients. His educational background includes a **Bachelor of Science** and a **Master of Science** in Biology from the **Universidad Complutense de Madrid**, as well as a **Global Executive MBA** from the **IESE Business School**. He has further refined his leadership capabilities through programs at **Harvard Business School**.

Supporting Global Health Initiatives

**Thermo Fisher Scientific** is recognised as a global leader in serving scientific needs, generating annual revenues exceeding **$40 billion**. The company’s mission is to enable customers to improve global health standards and enhance research capabilities. Their offerings cater to a diverse range of sectors, including life sciences research, diagnostics, and the development of transformative therapies.

As the pharmaceutical landscape evolves, Thermo Fisher’s integrated service model addresses the pressing demands faced by organizations today. By providing a comprehensive suite of solutions, they aim to foster innovation and support their clients in delivering impactful therapies to patients worldwide.

For further details on how the **Accelerator Drug Development** solution can meet specific organisational needs, interested parties can visit **www.thermofisher.com**.